Chapter

Risperidone long-acting injection*

Pierre Chue

in Antipsychotic long-acting injections

Published on behalf of Oxford University Press

Published in print October 2010 | ISBN: 9780199586042
Published online February 2013 | e-ISBN: 9780191754708 | DOI: http://dx.doi.org/10.1093/med/9780199586042.003.0005
Risperidone long-acting injection*

Show Summary Details

Preview

Risperidone is a second-generation (SGA) or atypical (novel) antipsychotic first marketed worldwide in the 1990s as an oral preparation. In 2003, the US Federal Drugs Administration (FDA) approved risperidone long-acting injection (RLAI), the first SGA to be available commercially in an injectable sustained-action formulation (Chue 2003; Ereschefsky & Mascarenas 2003). This chapter describes the development of RLAI, reviews aspects of the pharmacokinetics, summarizes the pivotal trials and clinical data including pharmacoeconomic, and discusses the potential future directions for this novel formulation.

Chapter.  19177 words.  Illustrated.

Subjects: Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.